U.S. Markets closed

Calithera Biosciences, Inc. (CALA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.4413-0.0111 (-2.45%)
At close: 04:00PM EST
0.4600 +0.02 (+4.24%)
After hours: 06:51PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.4524
Bid0.4450 x 3200
Ask0.4600 x 900
Day's Range0.4024 - 0.4632
52 Week Range0.3900 - 3.3350
Avg. Volume2,055,891
Market Cap33.065M
Beta (5Y Monthly)1.62
PE Ratio (TTM)N/A
EPS (TTM)-0.9410
Earnings DateMar 14, 2022 - Mar 18, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.83
  • InvestorPlace

    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

    Good morning, trader! It’s time to dive into another day of investing with the biggest pre-market stock movers for Thursday! Source: f11photo/ Moving stocks this morning are FDA updates, merger agreements, public offerings, and more! Let’s jump into that news below!InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pre-Market Stock Movers: 10 Top Gainers Calithera Biosciences (NASDAQ:CALA) stock is rising nearly 36% alongside heavy trading of the company’s shares. Bau

  • PR Newswire

    AN2 Therapeutics Closed $80 Million Series B Financing to Advance Novel Nontuberculous Mycobacterial Lung Disease Program

    AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet medical need, today announced several significant strides in the company's development over the past year.

  • GlobeNewswire

    Calithera to Present at the H.C. Wainwright BioConnect Virtual Conference

    SOUTH SAN FRANCISCO, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Molineaux, Ph.D., the company’s founder, president and chief executive officer, will present at the H.C. Wainwright BioConnect Virtual Conference. The session will feature the Company's new corporate presentation which is currently available through the Investors section of the Company's website at ww